

No. 24-316

In the Supreme Court of the United States

ROBERT F. KENNEDY, JR., SECRETARY OF HEALTH AND
HUMAN SERVICES, ET AL.,

Petitioners,

v.

BRAIDWOOD MANAGEMENT, INC., ET AL.,

Respondents.

**On Writ of Certiorari to
the United States Court of Appeals
for the Fifth Circuit**

**BRIEF OF THE AMERICAN PUBLIC HEALTH
ASSOCIATION, PUBLIC HEALTH DEANS AND
SCHOLARS, THE ROBERT WOOD JOHNSON
FOUNDATION, AND PUBLIC HEALTH
ADVOCATES AS *AMICI CURIAE*
IN SUPPORT OF PETITIONERS**

ANDREW J. PINCUS
Counsel of Record
Mayer Brown LLP
1999 K Street, NW
Washington, DC 20006
(202) 263-3000
apincus@mayerbrown.com

Counsel for Amici Curiae

TABLE OF CONTENTS

	Page
INTEREST OF THE <i>AMICI CURIAE</i>	1
INTRODUCTION AND	2
SUMMARY OF ARGUMENT.....	2
ARGUMENT	5
I. THE COURT OF APPEALS’ RULING WILL CAUSE AMERICANS TO SUFFER PREVENTABLE ILLNESS AND EVEN DEATH.....	5
A. The court of appeals’ decision jeopardizes guaranteed cost-free coverage for life-saving services.....	5
B. The ACA’s requirement of cost-free coverage has significantly increased Americans’ use of these critical services.....	14
C. Without the federal requirement, companies and insurers will re-impose cost-sharing, which will reduce the use of life-saving services.....	18
II. THE PREVENTIVE SERVICES REQUIREMENT IS CONSTITUTIONAL.....	21
CONCLUSION	23
APPENDIX.....	1a

TABLE OF AUTHORITIES

	Page(s)
 CASES	
<i>Free Enter. Fund v. Pub. Acct. Oversight Bd.</i> , 561 U.S. 477 (2010).....	21
<i>Seila Law LLC v. Consumer Fin. Prot. Bureau</i> , 591 U.S. 197 (2020).....	22
<i>United States v. Arthrex, Inc.</i> , 594 U.S. 1 (2021).....	21
 STATUTES	
42 U.S.C. § 300	3, 5, 18
42 U.S.C. § 299b-4(a)(6)	21
 OTHER AUTHORITIES	
155 Cong. Rec. 32890 (2009) (statement of Sen. Cardin)	13
American Cancer Society, <i>Key Statistics for Lung Cancer</i> (Jan. 29, 2024), https://bit.ly/3oEF1Yo	6

TABLE OF AUTHORITIES—continued

	Page(s)
American Cancer Society, <i>Tamoxifen and Raloxifene for Lowering Breast Cancer Risk</i> (Dec. 16, 2021), https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/tamoxifen-and-raloxifene-for-breast-cancer-prevention.html	8
Krutika Amin et al., <i>Preventive Services Use Among People With Private Insurance Coverage</i> (Mar. 20, 2023), https://bit.ly/3oxjfWO	15
Samantha Artiga et al., <i>The Effects of Premiums and Cost Sharing on Low-Income Populations; Updated Review of Research Findings</i> (Jun. 1, 2017), https://www.kff.org/medicaid/issue-brief/the-effects-of-premiums-and-cost-sharing-on-low-income-populations-updated-review-of-research-findings/	17
Jay Asser, <i>Patients Likely to Skip Preventive Care if ACA Ruling Holds</i> , Healthleaders (Mar. 17, 2023), https://bit.ly/3AiiP94	16

TABLE OF AUTHORITIES—continued

	Page(s)
Assistant Sec’y for Planning & Evaluation, U.S. Dep’t of Health and Human Servs., <i>Access to Preventive Services Without Cost-Sharing: Evidence from the Affordable Care Act</i> (Jan. 11, 2022), https://bit.ly/41rGtfm	6
Assistant Sec’y for Planning & Evaluation, U.S. Dep’t of Health and Human Servs., <i>The Affordable Care Act Is Improving Access to Preventive Services for Millions of Americans</i> (May 14, 2015), https://bit.ly/43RpzIP	18
Ruchita Balasubramanian et al., <i>Projected Impact of Expanded Long- Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics</i> , 91 J. of Acquired Immune Deficiency Syndrome 144 (2022), https://bit.ly/3H7bz3L	11
Board of Governors of the Federal Reserve System, <i>Economic Well- Being of U.S. Households in 2022</i> (May 2023), https://bit.ly/3plW967	17

TABLE OF AUTHORITIES—continued

	Page(s)
Robert H. Brook et al., <i>The Health Insurance Experiment: A Classic RAND Study Speaks to the Current Healthcare Reform Debate</i> (2006), https://bit.ly/3H3byhn	16
Centers for Disease Control and Prevention, <i>Clinical Screening and Diagnosis for Hepatitis C</i> (Dec. 19, 2023), https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/index.html	10
Employee Benefit Res. Inst., <i>Employer Uptake of Pre-Deductible Coverage for Preventive Services in HSA-Eligible Health Plans</i> (Oct. 14, 2021), https://bit.ly/3N7RqhR	19
Employee Benefit Res. Inst., <i>Will Employers Introduce Cost Sharing for Preventive Services? Findings from EBRI's First Employer Pulse Survey</i> (Oct. 27, 2022), https://bit.ly/41tbAY3	19

TABLE OF AUTHORITIES—continued

	Page(s)
Brigit Hatch et al., <i>Impacts of the Affordable Care Act on Receipt of Women’s Preventive Services in Community Health Centers in Medicaid Expansion and Nonexpansion States</i> , 31 <i>Women’s Health Issues</i> 9 (2021), https://bit.ly/43UD1vp	15
Xuesong Han et al., <i>Has Recommended Preventive Service Use Increased After Elimination of Cost-Sharing As Part of the Affordable Care Act in the United States?</i> , 78 <i>Prev. Med.</i> 85 (2015), https://bit.ly/41sg8ht	15, 16
Kaiser Family Foundation, <i>Population Distribution by Age</i> (last visited Feb. 23, 2025), https://bit.ly/3HkyDfu	15
Kaiser Family Foundation, <i>Preventive Services Covered by Private Health Plans Under the ACA</i> (Aug. 2015), https://bit.ly/3oBU98W	13, 16
Michele Late, <i>Court Ruling on Prevention Coverage ‘Disastrous for Public Health’</i> , <i>Pub. Health Newswire</i> (Mar. 31, 2023), https://bit.ly/3UWSqXX	20

TABLE OF AUTHORITIES—continued

	Page(s)
Morning Consult, <i>National Tracking Poll #2301147 January 28-29, 2023</i> , https://assets.morningconsult.com/wp-uploads/2023/03/06150931/2301147_crosstabs_MC_HEALTH_CA_COURT_CASE_Adults.pdf	16
Nat'l Ctr. for Health Statistics, Ctrs. for Disease Control & Prevention, <i>Interactive Summary Health Statistics for Adults - 2019-2023</i> (last visited Feb. 23, 2025), https://bit.ly/3LoZf1j	15
Hope C. Norris et al., <i>Utilization Impact of Cost-Sharing Elimination for Preventive Care Services: A Rapid Review</i> , 79 <i>Med. Care Res. & Rev.</i> 175 (2022)	15-17, 19
A. David Paltiel et al., <i>Increased HIV Transmissions With Reduced Insurance Coverage for HIV Preexposure Prophylaxis: Potential Consequences of Braidwood Management v. Becerra</i> , 10 <i>Open Forum Infectious Diseases</i> 1 (2023), https://bit.ly/3H4nM9t	12

TABLE OF AUTHORITIES—continued

	Page(s)
<p>Sarosh Rana et al., <i>Preeclampsia: Pathophysiology, Challenges, and Perspectives</i>, 124 <i>Circulation Res.</i> 1094 (2019), https://bit.ly/3H4DVeV</p>	12
<p>Laura Skopec & Jessica Banthin, <i>Free Preventive Services Improve Access to Care</i> (July 2022), https://bit.ly/3pcDQjE</p>	17
<p>Geetesh Solanki & Helen Halpin Schaffler, <i>Cost-sharing and the Utilization of Clinical Preventive Services</i>, 17 <i>Am. J. Preventive Med.</i> 127 (1999), https://bit.ly/3NmKFcN.....</p>	16
<p>Amal N. Trivedi et al., <i>Effect of Cost-Sharing on Screening Mammography in Medicare Health Plans</i>, 358 <i>N. England J. Med.</i> 375 (2008), https://bit.ly/3Amo6fU</p>	16
<p>U.S. Preventive Servs. Taskforce, <i>Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement</i>, 326 <i>J. Am. Med. Ass'n</i> 1186 (2021), https://bit.ly/3oD9oig</p>	12

TABLE OF AUTHORITIES—continued

	Page(s)
U.S. Preventive Servs. Taskforce, <i>Interventions to Prevent Falls in Community-Dwelling Older Adults: US Preventive Services Task Force Recommendation Statement</i> , 319 J. Am. Med. Ass’n 1696 (2018), https://jamanetwork.com/journals/jama/fullarticle/2678104	13
U.S. Preventive Servs. Taskforce, <i>Medication Use to Reduce Risk of Breast Cancer</i> , 322 J. Am. Med. Ass’n 857 (2019), https://jamanetwork.com/journals/jama/fullarticle/2749221	7, 8
U.S. Preventive Servs. Taskforce, <i>Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement</i> , 330 J. Am. Med. Ass’n 736 (2023), https://bit.ly/3UUF5Q7	11
U.S. Preventive Servs. Taskforce, <i>Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement</i> , 322 J. Am. Med. Ass’n 652 (2019), https://bit.ly/3mUZ44C	13

TABLE OF AUTHORITIES—continued

	Page(s)
U.S. Preventive Servs. Taskforce, <i>Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement, 325 J. Am. Med. Ass’n 1965 (2021), https://bit.ly/3oy6oDA</i>	6
U.S. Preventive Servs. Taskforce, <i>Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement, 324 J. Am. Med. Ass’n 2415 (2020), https://bit.ly/3H4Zj3W</i>	9
U.S. Preventive Servs. Taskforce, <i>Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement, 323 J. Am. Med. Ass’n 970 (2020), https://bit.ly/3KVwmIN</i>	10
U.S. Preventive Servs. Taskforce, <i>Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement, 325 J. Am. Med. Ass’n 962 (2021), https://bit.ly/3n32Etg</i>	6

TABLE OF AUTHORITIES—continued

	Page(s)
U.S. Preventive Servs. Taskforce, <i>Screening for Prediabetes and Type 2 Diabetes</i> , 326 J. Am. Med. Ass’n 736 (2021), https://jamanetwork.com/journals/jama/fullarticle/2783414	8, 9
U.S. Preventive Servs. Taskforce, <i>Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement</i> , 328 J. Am. Med. Ass’n 746 (2022), https://bit.ly/3N56mgW	7
Rosita Van Den Puttelaar, et al., <i>Impli- cations of the Initial Braidwood v. Becerra Ruling for Colorectal Cancer Outcomes: a Modeling Study</i> , J. Nat’l Cancer Inst. 1 (2024), https://doi.org/10.1093/jnci/djae244	20

INTEREST OF THE *AMICI CURIAE*¹

The American Public Health Association (APHA), founded in 1872, is the leading professional organization for public health professionals in the United States. APHA shares the latest research and information, promotes best practices, and advocates for public health issues and policies grounded in scientific research. APHA represents more than 24,000 individual members and is the only organization that combines a 150-year perspective, a broad-based member community, and a focus on influencing federal policy to improve the public's health.

The individual *amici* are 115 distinguished deans and professors of public health and of health law and policy with deep expertise in policies that promote population health and alleviate barriers to care. They are identified in the Appendix.

The Robert Wood Johnson Foundation (RWJF) is a leading national philanthropy dedicated to taking bold leaps to transform health in our lifetime. A core feature of RWJF's philanthropic approach is funding research to identify evidence-based methods of improving health outcomes for all. As part of those efforts, RWJF has supported research demonstrating the benefits of comprehensive coverage for no-cost preventive health services.

Trust for America's Health (TFAH) is a nonpartisan, nonprofit organization focused on public health research and policy. TFAH is committed to promoting optimal health for every person and community and

¹ Pursuant to Rule 37.6, *amici* affirm that no counsel for a party authored this brief in whole or in part and that no person other than *amici* and their counsel made a monetary contribution to its preparation or submission.

making health equity foundational to policymaking at all levels. The organization's work is focused on the antecedents of poor health and on policies and programs to advance an evidence-based public health system that is ready to meet the challenges of the 21st century. TFAH develops reports and other resources and initiatives to educate the public and recommends policies to promote health and wellbeing and to make the prevention of illness and injury a national priority.

APHA has a strong interest in ensuring the continued availability of cost-free coverage for preventive healthcare, given its mission to promote public health through evidence-based policies. The individual *amici*, RWJF, and TFAH all share that interest. *Amici* file this brief to explain the importance of the cost-free preventive services requirements and the significant harm to public health that will result if those requirements are invalidated.

INTRODUCTION AND SUMMARY OF ARGUMENT

The court of appeals' decision effectively invalidates a critically important provision of the Affordable Care Act (ACA) that ensures more than 150 million Americans' access to essential life-saving tests and treatments. *Amici* submit this brief to explain that, if the ruling is permitted to stand, deadly diseases will not be detected and important treatments will be unavailable—resulting in serious illnesses, chronic medical conditions, and deaths that otherwise would have been prevented.

Prior to enactment of the ACA, a significant number of health insurance plans failed to cover preventive tests and other medical services for the detection

and prevention of major diseases. Plans that did provide coverage often required patients to pay a share of the cost—out of pocket and at the time of service—which deterred many patients from obtaining these life-saving services.

To protect Americans' health, the ACA requires private insurance plans to cover, cost-free, four essential categories of preventive services. This requirement extends beyond ACA marketplace health insurance plans and includes virtually all employer-sponsored health insurance and other private insurance.

One of those preventive services categories is “evidence-based items or services” with an A or B recommendation from the U.S Preventive Services Task Force (USPSTF). See 42 U.S.C. § 300gg-13(a)(1). The USPSTF is a panel of experts that rigorously evaluates peer-reviewed scientific evidence and recommends especially valuable preventive services. See Pet. Br. 4-5.

These services save, and dramatically improve, Americans' lives by identifying and addressing health risks early, so they can be treated more effectively—by preventing diseases from occurring at all and by protecting all Americans against the risk of transmission of communicable diseases. They are critical to reducing the incidence and severity of numerous diseases and life-threatening conditions, and are especially important to maternal and child health. The ACA's requirement of cost-free coverage has dramatically increased use of these vital services by all Americans.

The court of appeals' decision threatens this requirement for dozens of life-saving services recommended by the USPSTF—every preventive service

given an A or B recommendation after the enactment of the ACA in 2010. Without the ACA's requirement, some companies and insurers will re-impose cost-sharing. Some may eliminate coverage completely.

Without cost-free coverage, many Americans will not use these services: studies consistently demonstrate that when people are required to pay part of the cost of preventive care, they often do not obtain it. That leads to more serious illnesses and even deaths among the individuals deprived of coverage. It also affects Americans more broadly, because many of the covered services prevent and treat illnesses that, if not detected and treated, can be spread among the population generally.

This brief discusses the particular preventive services affected, and the adverse public health consequences of the elimination of the cost-free coverage guarantee for those services.

But the court of appeals' determination, if upheld, will do more than eliminate cost-free coverage for existing post-2010 USPSTF recommendations. It will mean that the covered services cannot be adjusted to account for advances in prevention and detection of serious diseases. New discoveries can include more effective detection techniques that reveal the onset of a disease earlier and more accurately. Or new medicines that better prevent the onset of disease, or that have fewer side-effects. Or that existing detection or preventive services should be extended to a broader age-group or other population because new evidence shows greater risk of contracting the disease.

This Court should implement Congress's clear intent to enable Americans to benefit from continued scientific advances in detecting and preventing

serious diseases and reject a determination that would set in stone 2010-era science.

The Court therefore should reverse the judgment below—and thereby preserve these critical benefits for more than 150 million Americans.

ARGUMENT

I. THE COURT OF APPEALS' RULING WILL CAUSE AMERICANS TO SUFFER PREVENTABLE ILLNESS AND EVEN DEATH.

Congress determined that to promote the public health—and prevent Americans from suffering from serious diseases, including diseases that can lead to death—it is necessary to remove barriers to Americans' use of preventive health services. Congress therefore included in the ACA provisions mandating that insurers cover many of those services cost-free. See 42 U.S.C. § 300gg-13(a).

Serious harm to Americans' health will be the inevitable consequence of upholding the court of appeals' determination and eliminating the preventive services requirement for all of the services rated A or B by USPSTF since 2010—which also will bar extension of the cost-free coverage requirement to new life-saving preventive services discovered as the result of advances in medical science.

A. The court of appeals' decision jeopardizes guaranteed cost-free coverage for life-saving services.

The holding below jeopardizes guaranteed cost-free coverage for at least two dozen services with USPSTF A or B recommendations published or updated after 2010. These life-saving services include:

- ***Lung cancer screening for high-risk persons:***² Lung cancer is the second most common cancer and the leading cause of cancer death in the United States.³ Studies demonstrate that this cancer is significantly more treatable when detected early,⁴ which is why the USPSTF recommended screenings in 2013 and expanded that recommendation to apply to more persons in 2021.⁵
- ***Colorectal cancer screening for adults 45-49:***⁶ Colorectal cancer is the Nation's third leading cause of death from cancer, and its incidence has increased for adults 40-49 years old.⁷ Colorectal cancer screening is especially beneficial because it involves removing precancerous growths.⁸ Screening not only detects cancer early, but keeps it from developing in the first place. The USPSTF's 2021

² U.S. Preventive Servs. Taskforce, *Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement*, 325 J. Am. Med. Ass'n 962 (2021), <https://bit.ly/3n32Etg> (*Screening for Lung Cancer*).

³ Am. Cancer Soc'y, *Key Statistics for Lung Cancer* (Jan. 29, 2024), <https://bit.ly/3oEF1Yo>.

⁴ *Screening for Lung Cancer* at 962.

⁵ *Id.* at 965.

⁶ U.S. Preventive Servs. Taskforce, *Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement*, 325 J. Am. Med. Ass'n 1965 (2021), <https://bit.ly/3oy6oDA>.

⁷ *Id.* at 1965.

⁸ Assistant Sec'y for Planning & Evaluation, U.S. Dep't of Health and Human Servs., *Access to Preventive Services Without Cost-Sharing: Evidence from the Affordable Care Act 8* (Jan. 11, 2022), <https://bit.ly/41rGtfm> (*Access to Preventive Services*).

recommendation provides this benefit to 15-17.5 million additional people, by expanding to include adults 45-49 years old.⁹

- ***Statins to Prevent Cardiovascular Disease***:¹⁰ Cardiovascular disease is the leading cause of death in the United States.¹¹ For those at increased risk, statins effectively reduce both cardiovascular-disease events and mortality.¹² The USPTSF therefore recommended statins for at-risk adults 40-75 years old in 2016 and 2022, enabling cost-free access to this potentially life-saving drug.¹³
- ***Medication to Reduce Risk of Breast Cancer***:¹⁴ Breast cancer is the second leading cause of cancer death; and an estimated one in eight women will develop breast cancer at some point in their lifetime.¹⁵ In 2018, an estimated 266,120 new cases of breast cancer were diagnosed in women in the United States, and an estimated 40,920 women died of breast cancer—14% of all cancer deaths in

⁹ *Ibid.*

¹⁰ U.S. Preventive Servs. Taskforce, *Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement*, 328 J. Am. Med. Ass’n 746 (2022), <https://bit.ly/3N56mgW>.

¹¹ *Id.* at 746.

¹² *Id.* at 748 tbl.

¹³ *Id.* at 747, 750.

¹⁴ U.S. Preventive Servs. Taskforce, *Medication Use to Reduce Risk of Breast Cancer*, 322 J. Am. Med. Ass’n 857 (2019), <https://jamanetwork.com/journals/jama/fullarticle/2749221>.

¹⁵ *Id.* at 862.

women.¹⁶ Multiple techniques exist for determining whether women over 35 face an increased risk of developing breast cancer.¹⁷ Medications—such as tamoxifen, raloxifene, or aromatase inhibitors—can reduce that risk of developing cancer by approximately 40%.¹⁸ The USPSTF recommendation covers the cost of the risk assessment and, if an increased risk is found, the cost of the risk-reducing medications.¹⁹

- ***Prediabetes and Type 2 Diabetes Screening***:²⁰ Diabetes is the leading cause of kidney failure and of new cases of blindness among adults in the United States; is associated with increased risks of cardiovascular disease and liver disease; and was estimated to be the seventh leading cause of death in the United States in 2017.²¹ Significant percentages of people with diabetes are not aware that they have the condition.²² Providing treatment to

¹⁶ *Ibid.*

¹⁷ *Id.* at 860-61.

¹⁸ American Cancer Society, *Tamoxifen and Raloxifene for Lowering Breast Cancer Risk* (Dec. 16, 2021), <https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/tamoxifen-and-raloxifene-for-breast-cancer-prevention.html>.

¹⁹ *Medication Use to Reduce Risk of Breast Cancer*, 322 J. Am. Med. Ass'n at 861-62.

²⁰ U.S. Preventive Servs. Taskforce, *Screening for Prediabetes and Type 2 Diabetes*, 326 J. Am. Med. Ass'n 736 (2021), <https://jamanetwork.com/journals/jama/fullarticle/2783414>.

²¹ *Id.* at 736.

²² *Ibid.* (“[o]f persons with diabetes, 21.4% were not aware of or did not report having diabetes, and only 15.3% of persons with

individuals found to have diabetes reduces mortality; and providing preventive interventions to those found to be prediabetic reduces progression to diabetes and can address the risk of cardiovascular disease associated with prediabetes. The USPSTF-recommended screening of those with the greatest risk—all adults aged 35-70 who are overweight or obese—thus provides important health benefits.²³ And the current recommendation is a significant expansion from the recommendation at the time the ACA was enacted, which was limited to adults with high blood pressure, and provided screening only for type 2 diabetes, not for prediabetes.²⁴

- ***Screening for Hepatitis B Infection in Adults:***²⁵ 862,000 Americans are estimated to be living with chronic infection of the hepatitis B virus.²⁶ For 15-40% of these individuals, chronic infection will develop into cirrhosis, liver cancer, or liver failure, which can be deadly.²⁷ Crucially, it is estimated that 68% of people with chronic hepatitis B are not aware of their infection, and may not have symptoms

prediabetes reported being told by a health professional that they had this condition”).

²³ *Id.* at 737-738.

²⁴ *Id.* at 739.

²⁵ U.S. Preventive Servs. Taskforce, *Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement*, 324 J. Am. Med. Ass’n 2415 (2020), <https://bit.ly/3H4Zj3W>.

²⁶ *Id.* at 2415.

²⁷ *Ibid.*

until the onset of serious illness—this not only results in delayed treatment, but also increases the likelihood of unknowing transmission to others.²⁸ Screening of at-risk individuals, as recommended by the USPSTF in 2014 and 2020, addresses these problems.²⁹

- ***Screening for Hepatitis C Infection in Adults:***³⁰ As of March 2020, Hepatitis C virus was “associated with more deaths [in the United States] than the top 60 other reportable infectious diseases *combined*.”³¹ An estimated 4.1 million Americans have past or current Hepatitis C infection.³² Nearly half of those with hepatitis C are unaware of their infection status, and approximately 75%–85% of people with hepatitis C do not have symptoms—which makes screening all the more important.³³ Early screening and treatment can prevent serious complications like liver scarring, liver cancer, and death; and there

²⁸ *Ibid.*

²⁹ *Id.* at 2416.

³⁰ U.S. Preventive Servs. Taskforce, *Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement*, 323 J. Am. Med. Ass’n 970 (2020), <https://bit.ly/3KVwmIN> (*Screening for Hepatitis C*).

³¹ *Id.* at 970 (emphasis added).

³² *Ibid.*

³³ Centers for Disease Control and Prevention, *Clinical Screening and Diagnosis for Hepatitis C* (Dec. 19, 2023), <https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/index.html>.

are now treatments available that are curative for most people.³⁴

The USPSTF recommended screening in 2013 and then greatly broadened the scope of the recommendation to adults 18-79 years old, concluding that early detection and treatment leads to significantly improved health outcomes.³⁵

- ***Preexposure Prophylaxis (PrEP) to Prevent HIV:***³⁶ An estimated 1.2 million Americans are living with HIV.³⁷ By preventing HIV acquisition among those who are HIV-negative, PrEP protects the health of those who use the medication and reduces further HIV transmission in the community.³⁸ One study found that if the number of individuals using PrEP increased by 25%, new HIV cases would decrease by 54%.³⁹ Conversely, a recent study suggests that there will be 1140 additional HIV transmissions among men who have sex with men for every 10% reduction in PrEP

³⁴ *Ibid.*

³⁵ *Screening for Hepatitis C*, 323 J. Am. Med. Ass'n at 972.

³⁶ U.S. Preventive Servs. Taskforce, *Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement*, 330 J. Am. Med. Ass'n 736 (2023), <https://bit.ly/3UUF5Q7>.

³⁷ *Id.* at 736.

³⁸ *Id.* at 741.

³⁹ Ruchita Balasubramanian et al., *Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics*, 91 J. of Acquired Immune Deficiency Syndrome 144, 146 (2022), <https://bit.ly/3H7bz3L>.

coverage caused by the court of appeals’ ruling.⁴⁰

- ***Aspirin Use to Prevent Preeclampsia***:⁴¹ Preeclampsia is “one of the most serious health problems that affect pregnant persons.”⁴² It is a leading cause of maternal death in the United States,⁴³ and can also lead to preterm births.⁴⁴ Daily low-dose use of aspirin—recommended by the USPSTF in 2021—reduces the risk of preeclampsia, preterm birth, and maternal mortality, thus protecting both maternal and infant health.⁴⁵

These are only a few of the services for which the court of appeals’ analysis would eliminate guaranteed cost-free coverage. Others include expanded screening for genetic mutations that increase women’s risk of

⁴⁰ A. David Paltiel et al., *Increased HIV Transmissions With Reduced Insurance Coverage for HIV Preexposure Prophylaxis: Potential Consequences of Braidwood Management v. Becerra*, 10 *Open Forum Infectious Diseases* 1, 1 (2023), <https://bit.ly/3H4nM9t>.

⁴¹ U.S. Preventive Servs. Taskforce, *Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement*, 326 *J. Am. Med. Ass’n* 1186 (2021), <https://bit.ly/3oD9oig> (*Aspirin Use to Prevent Preeclampsia*).

⁴² *Id.* at 1186.

⁴³ Sarosh Rana et al., *Preeclampsia: Pathophysiology, Challenges, and Perspectives*, 124 *Circulation Res.* 1094, 1094 (2019), <https://bit.ly/3H4DVeV>.

⁴⁴ *Aspirin Use to Prevent Preeclampsia* at 1186.

⁴⁵ *Id.* at 1187.

breast cancer by 45-65% by age 70;⁴⁶ and exercise interventions for at-risk adults 65 and older to prevent falls, which are the leading cause of injury-related morbidity and mortality among older American adults.⁴⁷

Saving lives and preventing illness are the most important benefits of cost-free coverage for these services, which not only promote the health of the insured but in many cases also protect third parties and the broader population from further transmission of disease. In addition, the services also reduce healthcare costs.⁴⁸ Illnesses that are prevented need not be treated at all, saving significant health costs. As one Senator explained, preventing patients from developing colon cancer through a screening that costs “a couple hundred dollars” is much more cost-effective than spending “tens of thousands of dollars” having to treat it.⁴⁹

Upholding the court of appeals’ determination will not just eliminate the cost-free coverage requirements with respect to the services just described. It is certain

⁴⁶ U.S. Preventive Servs. Taskforce, *Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement*, 322 J. Am. Med. Ass’n 652, 653 (2019), <https://bit.ly/3mUZ44C>.

⁴⁷ U.S. Preventive Servs. Taskforce, *Interventions to Prevent Falls in Community-Dwelling Older Adults: US Preventive Services Task Force Recommendation Statement*, 319 J. Am. Med. Ass’n 1696, 1696 (2018), <https://jamanetwork.com/journals/jama/fullarticle/2678104>.

⁴⁸ Kaiser Family Foundation, *Preventive Services Covered by Private Health Plans Under the ACA 1* (Aug. 2015), <https://bit.ly/3oBU98W>.

⁴⁹ 155 Cong. Rec. 32890 (2009) (statement of Sen. Cardin).

that advances in medical science will develop new, improved methods of detecting or preventing serious illness—after all, the expanded and new services discussed above were adopted over the last 14 years. But the cost-free coverage of new services that satisfy the USPSTF’s guidelines would be precluded by the court of appeals’ determination. And that result would be especially harmful when science develops a new detection or prevention methodology that yields better results than an older procedure. The court of appeals’ determination would provide cost-free coverage only for the outdated services and not for the improved services.

This Court should implement Congress’s clear intent to enable Americans to benefit from continued scientific advances in detecting and preventing serious diseases and reject a determination that would set in stone 2010-era science.

B. The ACA’s requirement of cost-free coverage has significantly increased Americans’ use of these critical services.

The Department of Health and Human Services (HHS) estimates that 151.6 million people, as of January 2020, were enrolled in private health insurance plans subject to the ACA’s preventive services requirement.⁵⁰ By eliminating cost-sharing, the ACA has increased access to and utilization of preventive services. Indeed, approximately 100 million Americans used the free preventive services guaranteed by

⁵⁰ *Access to Preventive Services* at 3, 5.

the ACA in 2018.⁵¹ The number is likely even higher today: the number of Americans with private health insurance coverage has increased since then, and therefore the use of preventive services surely has increased as well.⁵²

There can be no doubt that eliminating cost-sharing has increased Americans' use of preventive services. An extensive review of 35 academic studies found that eliminating cost-sharing "led to increases in utilization" of preventive services since the ACA was enacted, including "substantial increases" among the financially vulnerable.⁵³ One study, for example, found increased use of a variety of preventive services at community health centers across 14 states.⁵⁴

⁵¹ Krutika Amin et al., *Preventive Services Use Among People With Private Insurance Coverage* (Mar. 20, 2023), <https://bit.ly/3oxjfWO>.

⁵² Nat'l Ctr. for Health Statistics, Ctrs. for Disease Control & Prevention, *Interactive Summary Health Statistics for Adults – 2019-2023* (last visited Feb. 23, 2025), <https://bit.ly/3LoZf1j> (selecting topic "Private health insurance at time of interview: Adults aged 18-64") (showing 1.4% rise in percentage of adults with private health insurance from 2019 to 2023). Based on estimated population distribution by age, that increase corresponds to over 4 million additional individuals with private health insurance. See Kaiser Family Foundation, *Population Distribution by Age* (last visited Feb. 23, 2025), <https://bit.ly/3HkyDfu>.

⁵³ Hope C. Norris et al., *Utilization Impact of Cost-Sharing Elimination for Preventive Care Services: A Rapid Review*, 79 *Med. Care Res. & Rev.* 175, 192, 194 (2022); see also *Access to Preventive Services* at 10; Xuesong Han et al., *Has Recommended Preventive Service Use Increased After Elimination of Cost-Sharing As Part of the Affordable Care Act in the United States?*, 78 *Prev. Med.* 85 (2015), <https://bit.ly/41sg8ht>.

⁵⁴ Brigit Hatch et al., *Impacts of the Affordable Care Act on Receipt of Women's Preventive Services in Community Health*

This increase is a direct result of the elimination of cost-sharing. Multiple studies demonstrate that “the presence of cost-sharing, even if the amount is relatively modest, deters patients from receiving care.”⁵⁵

One study, for example, found that patient cost-sharing produced a 9-10% decline in use of mammograms and 8-10% decline in use of pap smears.⁵⁶ Indeed, prior to the ACA, 9% of insured men and 13% of insured women—and 31% of low-income men and 35% of low-income women—reported postponing preventive services because of cost.⁵⁷ And a survey of 2,199 Americans conducted after the district court’s ruling found that 40% of respondents would not utilize most preventive services without cost-free coverage.⁵⁸ One

Centers in Medicaid Expansion and Nonexpansion States, 31 Women’s Health Issues 9, 15 (2021), <https://bit.ly/43UD1vp>.

⁵⁵ Norris, *supra* n.53, at 175; see also Han, *supra* n.53, at 85 (collecting studies); Amal N. Trivedi et al., *Effect of Cost-Sharing on Screening Mammography in Medicare Health Plans*, 358 N. England J. Med. 375, 375 (2008), <https://bit.ly/3Amo6fU> (noting that even “[r]elatively small copayments” have been found to be associated with decreased use of effective preventive care); Robert H. Brook et al., *The Health Insurance Experiment: A Classic RAND Study Speaks to the Current Healthcare Reform Debate* (2006), <https://bit.ly/3H3byhn>.

⁵⁶ Geetesh Solanki & Helen Halpin Schaffler, *Cost-sharing and the Utilization of Clinical Preventive Services*, 17 Am. J. Preventive Med. 127 (1999), <https://bit.ly/3NmKFCn>.

⁵⁷ Kaiser Family Foundation, *supra* n.48, at 1.

⁵⁸ Jay Asser, *Patients Likely to Skip Preventive Care if ACA Ruling Holds*, Healthleaders (Mar. 17, 2023), <https://bit.ly/3AiiP94>. For example, 46% of respondents said they would not pay for prediabetes screening and 42% would not pay for cardiovascular preventive services. Morning Consult, *National Tracking Poll*

study found that studies have found that cost sharing even “in the range of \$1 to 5, are associated with the reduced use of care, including necessary services.”⁵⁹

These results are unsurprising, given that cost generally is a major barrier to healthcare access. In 2022, 28% of American adults, including 26% of insured adults, went without medical care because they could not afford it.⁶⁰ Moreover, since preventive services “do not address acute health problems” —but rather prevent such problems from occurring—people are more likely to “skip [preventive] care” in particular.⁶¹ And in deciding whether to pay for preventive care, individuals likely will not consider the substantial benefits to third parties and population health generally that flow from broad use of preventive services.

In sum, abundant academic research demonstrates that “[c]onsumer cost-sharing * * * diminish[es] utilization of preventive services.”⁶²

#2301147 January 28-29, 2023, at 94, 110, https://assets.morningconsult.com/wp-uploads/2023/03/06150931/2301147_cross-tabs_MC_HEALTH_ACA_COURT_CASE_Adults.pdf.

⁵⁹ Samantha Artiga et al., *The Effects of Premiums and Cost Sharing on Low-Income Populations; Updated Review of Research Findings* (Jun. 1, 2017), <https://www.kff.org/medicaid/issue-brief/the-effects-of-premiums-and-cost-sharing-on-low-income-populations-updated-review-of-research-findings/>.

⁶⁰ Board of Governors of the Federal Reserve System, *Economic Well-Being of U.S. Households in 2022*, at 34-35 (May 2023), <https://bit.ly/3plW967>.

⁶¹ Laura Skopec & Jessica Banthin, *Free Preventive Services Improve Access to Care 2* (July 2022), <https://bit.ly/3pcDQjE>.

⁶² Norris, *supra* n.53, at 175.

C. Without the federal requirement, companies and insurers will re-impose cost-sharing, which will reduce the use of life-saving services.

The court of appeals' decision would allow companies and insurers to re-impose cost-sharing for preventive services recommended since 2010. Some companies and insurers will do just that—and many may do so with just sixty days' notice to covered individuals.⁶³

That was the case before the ACA, and it is the reason why Congress enacted the preventive services requirement. Thus, HHS estimated in 2015 that the preventive services requirement had brought 76 million Americans expanded cost-free access that they previously lacked.⁶⁴

A survey of large employers confirms this reality. Eight percent of employers reported that, without the ACA's requirement, they would impose cost-sharing for preventive services while another 12% were

⁶³ See Declaration of Jeff Wu, Deputy Director for Policy in the Center for Consumer Information & Insurance Oversight, Centers for Medicare & Medicaid Services, ROA.2170-71; Declaration of Lisa Gomez, Assistant Secretary for Employee Benefits, Dep't of Labor, ROA.2178; see also 42 U.S.C. § 300gg-15(d)(4) (requiring group health plans and health insurance issuers to provide 60 days' notice of material modifications).

⁶⁴ Assistant Sec'y for Planning & Evaluation, U.S. Dep't of Health and Human Servs., *The Affordable Care Act Is Improving Access to Preventive Services for Millions of Americans* 1 (May 14, 2015), <https://bit.ly/43RpzIP>.

uncertain whether they would.⁶⁵ Even if only 8-20% of employers impose cost-sharing, millions of Americans would be affected. And once some insurers and companies impose cost-sharing, it may become a competitive disadvantage not to, because much of the cost savings from preventive care will not accrue until after the end of the covered year—because that is when costlier treatments will be avoided. This may lead even more insurers and companies to drop cost-free coverage.

Indeed, that is what companies have done in other contexts where cost-free coverage is not required. For example, although IRS regulations allow companies' health savings account (HSA)-eligible plans to cover the cost of certain services related to chronic conditions even when the insured has not satisfied the deductible, a recent study shows only 8% of companies covered the costs of all of those services.⁶⁶

Many patients will forgo life-saving preventive services if required to pay for them, because even “modest” cost-sharing “deters patients from receiving care.”⁶⁷ In addition, by replacing the ACA's clear rules for preventive services coverage with the choices of particular insurers, the court of appeals' ruling will leave providers and patients uncertain as to what services are or are not covered cost-free. Faced with that uncertainty, providers may stop recommending, and

⁶⁵ Employee Benefit Res. Inst., *Will Employers Introduce Cost Sharing for Preventive Services? Findings from EBRI's First Employer Pulse Survey 2* (Oct. 27, 2022), <https://bit.ly/41tbAY3>.

⁶⁶ Employee Benefit Res. Inst., *Employer Uptake of Pre-Deductible Coverage for Preventive Services in HSA-Eligible Health Plans 1* (Oct. 14, 2021), <https://bit.ly/3N7RqhR>.

⁶⁷ Norris, *supra* n.53, at 175.

patients may stop using, crucial services—even if some plans retain cost-free coverage.⁶⁸ Providers who are uncertain what is covered may err on the side of not providing or prescribing services, while patients may not even seek services they suspect might not be covered.

One recent study documents the impact of re-introducing cost-sharing for victims of colorectal cancer. If the decision below is upheld, cost-sharing will not be required for the USPSTF’s 2021 screening recommendations, which lowered the recommended age from 50 to 45 and expanded its screening recommendation to cover, for all age groups, polyp removal as well as follow-up colonoscopies after a positive noninvasive test. See also page 6 & nn.6-9, *supra*.

The study found that “the benefits of [colorectal cancer] screening would be substantially reduced through later screening initiation and lower ongoing screening participation.”⁶⁹ It found that the projected decline in screening participation due to cost sharing would lead over time to an increase in colorectal cancer incidence by 5.1% and an increase in deaths due to colorectal cancer of 9.1%.⁷⁰

⁶⁸ Michele Late, *Court Ruling on Prevention Coverage ‘Disastrous for Public Health’*, Pub. Health Newswire (Mar. 31, 2023), <https://bit.ly/3UWSqXX> (“The confusion and uncertainty will no doubt be a deterrent to early and effective life-saving interventions.”).

⁶⁹ Rosita Van Den Puttelaar, et al., *Implications of the Initial Braidwood v. Becerra Ruling for Colorectal Cancer Outcomes: a Modeling Study*, J. Nat’l Cancer Inst. 1, 2 (2024), <https://doi.org/10.1093/jnci/djae244>.

⁷⁰ *Id.* at 1.

In sum, the court of appeals' decision will lead to fewer patients receiving life-saving preventive healthcare. Patients across the Nation may miss cancer screenings and other important services, including critical maternal healthcare. Others will contract diseases that could have been avoided. Without early detection and treatment, more Americans will suffer serious illness and even death.

II. THE PREVENTIVE SERVICES REQUIREMENT IS CONSTITUTIONAL.

Amici agree with the government that Congress's reliance on the expertise of the USPSTF to identify one category of preventive services warranting cost-free coverage does not violate the Appointments Clause. See Pet. Br. 19-38.

Moreover, any possible constitutional concern can be addressed by severing 42 U.S.C. § 299b-4(a)(6), the provision stating that USPSTF members and the Task Force's recommendations "shall be independent and, to the extent practicable, not subject to political pressure." As the government explains (at 38-45), that is the only provision that could possibly negate the Secretary's authority to oversee the USPSTF.

This Court consistently holds that "severing any 'problematic portions [of a statute] while leaving the remainder intact'" is the proper approach "when confronting a constitutional flaw in a statute." *Free Enter. Fund v. Pub. Acct. Oversight Bd.*, 561 U.S. 477, 508 (2010) (quoting *Ayotte v. Planned Parenthood of N. New England*, 546 U.S. 320, 328-329 (2006)); see also *United States v. Arthrex, Inc.*, 594 U.S. 1, 23 (2021) (Roberts, C.J., joined by Alito, Kavanaugh, and Barrett, JJ.); *id.* at 44 (Breyer, J., joined by Sotomayor and Kagan, JJ.) (concurring in remedial holding);

Seila Law LLC v. Consumer Fin. Prot. Bureau, 591 U.S. 197, 232-38 (2020) (Roberts, CJ., joined by Alito and Kavanaugh, JJ.); *id* at 261 (Kagan, J., joined by Ginsburg, Breyer, and Sotomayor, JJ.) (concurring in the judgment with respect to severability).

That course is particularly appropriate here, given the important protections that the USPSTF preventive services provision provides to more than 150 million Americans.

CONCLUSION

The judgment of the court of appeals should be reversed.

Respectfully submitted.

ANDREW J. PINCUS
Counsel of Record
Mayer Brown LLP
1999 K Street, NW
Washington, DC 20006
(202) 263-3000
apincus@mayerbrown.com

Counsel for Amici Curiae

FEBRUARY 2025

APPENDIX*

Public Health Deans

1. Thomas E. Burroughs, PhD, MS, MA, Dean and Professor, SLU College for Public Health and Social Justice, Saint Louis University
2. G. Thomas Chandler, MS, PhD, Dean and Professor of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina
3. Julianna Deardorff, PhD, Executive Associate Dean of Faculty and Academic Affairs and Associate Professor, University of California Berkeley School of Public Health
4. Ayman El-Mohandes, MBBCh, MD, MPH, Dean, CUNY Graduate School of Public Health & Health Policy
5. Daniele Fallin, PhD, James W. Curran Dean of Public Health, Rollins School of Public Health, Emory University
6. Linda P. Fried, MD, MPH, Dean and DeLamar Professor of Public Health, Mailman School of Public Health, Professor of Epidemiology and Medicine, Columbia University

* Organizational affiliations listed for identification purposes only.

7. Sandro Galea, MD, DrPH, Dean, Robert A. Knox Professor, Boston University
8. Hilary Godwin, PhD, Dean, University of Washington School of Public Health
9. Lynn R. Goldman, MD, MPH, MS, Michael and Lori Milken Dean of Public Health, Milken Institute School of Public Health, The George Washington University
10. Colleen M. Grogan, PhD, Deputy Dean for Curriculum Policy, Deborah R. and Edgar D. Jannotta Professor, Crown Family School of Social Work, Policy, and Practice, The University of Chicago
11. Michael K. Gusmano, PhD, Professor and Associate Dean of Academic Programs, College of Health, Director, Center for Ethics, Lehigh University
12. Pamela R. Jeffries, PhD, RN, FAAN, ANEF, FSSH, Dean, Vanderbilt School of Nursing, Valere Potter Distinguished Professor of Nursing, RWJF Nurse Executive Fellow Alumna, Vanderbilt School of Nursing
13. Michael C. Lu, MD, MS, MPH, Dean, UC Berkeley School of Public Health
14. Boris Lushniak, MD, MPH, Professor and Dean, University of Maryland School of Public Health

15. Terry McGovern, JD, Professor and Senior Associate Dean for Academic and Student Affairs, CUNY School of Public Health
16. Edith A. Parker, MPH, DrPH, Dean, Professor, Community and Behavioral Health, The University of Iowa College of Public Health
17. Donna J. Petersen, ScD, MHS, CPH, Dean, College of Public Health, Professor of Public Health, University of South Florida
18. Megan L. Ranney, MD, MPH, FACP, Dean, C.-E.A. Winslow Professor of Public Health, Yale School of Public Health
19. Jane Thorpe, JD, Professor and Sr. Associate Dean for Academic, Student & Faculty Affairs, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
20. Edward Trapido, ScD, FACE, Dean, LSU School of Public Health – New Orleans
21. Sten H. Vermund, MD, PhD, Senior Associate Vice President, USF Health Dean, USF Health College of Public Health

**Public Health and Health Law and Policy
Scholars**

22. Joan Alker, MPhil, Research Professor, McCourt School of Public Policy, Georgetown University

23. Marice Ashe, JD, MPH, Lecturer, University of California Berkeley Law
24. Jennifer S. Bard, JD, MPH, PhD, Professor of Law, College of Law, Professor, Department of Internal Medicine, University of Cincinnati
25. Alison Barkoff, JD, Professor, Harold and Jane Hirsh Associate Professor of Health Law and Policy, Director, Hirsh Health Law and Policy Program, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
26. Julia Zoe Beckerman, JD, MPH, Teaching Professor & Vice Chair, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
27. Lynn A. Blewett, PhD, MA, Professor, Division of Health Policy and Management, University of Minnesota School of Public Health
28. David Blumenthal, MD, MPP, Professor of Practice of Public Health and Health Policy, Harvard T.H. Chan School of Public Health, Samuel O. Thier Professor of Medicine, Emeritus, Harvard Medical School
29. Robert Bonar, DHA, Gordon A. Friesen Professor of Healthcare Administration, Director of Master of Health Administration Program,

Milken Institute School of Public Health, The George Washington University

30. William B. Borden, MD, FACC, FAHA, Interim Chair, Department of Medicine, Chief Quality and Population Officer, Associate Professor of Medicine and Health Policy, George Washington University Medical Faculty Associates
31. Claire D. Brindis, DrPH, Distinguished Professor, Departments of Pediatrics and Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Emerita Director, Philip R. Lee Institute for Health Policy Studies, Co-Founder and Senior Scholar, Center for Global Reproductive Health and Co-Director, Adolescent and Young Adult Health National Resource Center
32. Taylor Burke, JD, LLM, Adjunct Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
33. Scott Burris, JD, Professor of Law, Director, Center for Public Health Law Research, Temple University Beasley School of Law
34. Maureen Byrnes MPA, Teaching Instructor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
35. Lara Cartwright-Smith, JD, MPH, Associate Professor, Department of Health Policy and

Management, Milken Institute School of Public Health, The George Washington University

36. Jillian Catalanotti, MD, MPH, FACP, Associate Professor of Medicine, Associate Professor of Health Policy and Management, Director, Internal Medicine Residency Programs, The George Washington University
37. Wendy Chavkin, MD, MPH, Professor Emerita of Population and Family Health and Obstetrics-Gynecology, Mailman School of Public Health and College of Physicians and Surgeons, Columbia University
38. Alan B. Cohen, Sc.D., Research Professor (Retired), Markets, Public Policy and Law, Boston University Questrom School of Business, and Professor of Health Law, Policy and Management (Retired), Boston University School of Public Health
39. Doron Dorfman, JSD, JSM, LL.M., LL.B., Professor of Law, Seton Hall University School of Law
40. Brenda Eskenazi, PhD, Jennifer and Brian Maxwell Distinguished Professor Emeritus of Maternal and Child Health and Epidemiology, School of Public Health, University of California at Berkeley
41. Scott Evans, PhD, MS, Director, The Biostatistics Center, Professor and Founding Chair, Department of Biostatistics and Bioinformatics,

Milken Institute School of Public Health, The George Washington University

42. Robert I. Field, JD, MPH, PhD, Professor of Law, Thomas R. Kline School of Law, Professor of Health Management and Policy, Dornsife University School of Public Health, Drexel University
43. Jacqueline Fox, JD, LL.M., Professor of Law, Joseph F. Rice School of Law, University of South Carolina
44. David M. Frankford, JD, Professor of Law, Rutgers University School of Law
45. Salama Freed, PhD, Assistant Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
46. Lance Gable, JD, MPH, Professor of Law, Wayne State University Law School
47. Melissa M. Goldstein, JD, Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
48. Neal Halfon, MD, MPH, Professor of Pediatrics, Public Health and Public Policy, Director, UCLA Center for Healthier Children, Families & Communities, UCLA

49. Bethany Hamilton, JD, Co-Director, National Center for Medical-Legal Partnership, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
50. Eva Harris, PhD, Professor and Chair, Division of Infectious Diseases and Vaccinology, School of Public Health, Professor, Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, Director, Center for Global Public Health, University of California, Berkeley
51. Janet Heinrich, DrPH, RN, FAAN, Research Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
52. Jennifer L. Herbst, JD, LLM, M.Bioethics, Professor of Law and Medical Sciences, Quinipiac University School of Law and Frank H. Netter School of Medicine
53. Laura Hermer, JD, LLM, Professor of Law, Mitchell Hamline School of Law
54. Allison K. Hoffman, JD, Professor of Law, Professor of Medical Ethics & Health Policy, University of Pennsylvania Carey Law School
55. Sharona Hoffman, JD, LLM, SJD, Professor of Bioethics, Edgar A. Hahn Professor of Law, Co-Director, Law-Medicine Center, Case Western Reserve University School of Law

56. Katherine Horton, RN, MPH, JD, Research Professor in the Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
57. Nicole Huberfeld, Edward R. Utley Professor of Health Law, Co-Director, BU Program on Reproductive Justice, Chair, BU Health Law Program, Boston University School of Law and School of Public Health
58. Susan L. Ivey, MD, MHSA, Professor, Adjunct, Co-PI and Co-Director of Research, Health Research for Action, University of California, Berkeley, School of Public Health
59. Feygele Jacobs, DrPH, MS, MPH, Professor and Director, Geiger Gibson Program in Community Health, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
60. Peter D. Jacobson, JD, MPH, Professor Emeritus of Health Law and Policy, University of Michigan School of Public Health
61. Stacie Kershner, JD, Deputy Director, Center for Law, Health and Society, George State University College of Law
62. Louise P. King, MD, JD, Assistant Professor, Brigham and Women's Hospital, Director of Research, Minimally Invasive Gynecologic Surgery, Associate Program Director, Fellowship in

Minimally Invasive Gynecologic Surgery, Director of Reproductive Bioethics, Center for Bioethics, Co-Director, Ethics, Essentials of the Profession, Harvard Medical School, Affiliated Faculty Petrie Flom Center, Harvard Law School

63. Leighton Ku, PhD, MPH, Professor, Department of Health Policy and Management, Director, Center for Health Policy Research, Milken Institute School of Public Health, The George Washington University
64. Renée M. Landers, JD, Professor of Law and Faculty Director, Health and Biomedical Law Concentration and Master of Science in Law, Suffolk University Law School
65. Paula Lantz, PhD, Interim Associate Director, International Policy Center, James B. Hudak Professor of Health Policy, BA Program Director, Gerald R. Ford School of Public Policy, Professor of Health Management and Policy, University Professor of Diversity and Social Transformation, School of Public Health, University of Michigan
66. Sylvia A. Law, JD, Elizabeth K. Dollard Professor Emerita of Law, Medicine and Psychiatry, NYU Law School
67. Jeffrey Levi, PhD, Professor Emeritus, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University

68. Marsha Lillie-Blanton, DrPH, Adjunct Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
69. Manya Magnus, PhD, MPH, Professor and Chair, Department of Epidemiology, Milken Institute School of Public Health, The George Washington University
70. Wendy K. Mariner, JD, LL.M, MPH, Professor of Health Law, Ethics and Human Rights Emerita, Boston University School of Public Health
71. Anne R. Markus, PhD, MHS, JD, Professor and Chair, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
72. Diana J. Mason, RN, PhD, FAAN, Senior Policy Service Professor, Center for Health Policy and Media Engagement, School of Nursing, The George Washington University
73. Karen A. McDonnell, PhD, Associate Professor and Vice Chair, Department of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University
74. Monica R. McLemore, RN, MPH, PhD, Visiting Professor, Rory Meyers College of Nursing, New York University

75. Molly McNulty, JD, Associate Professor of Public Health Law and Policy, Undergraduate Program in Public Health, School of Arts and Sciences, University of Rochester, Department of Public Health Sciences, University of Rochester School of Medicine & Dentistry
76. David Michaels, PhD, MPH, Professor, Department of Environmental and Occupational Health, Milken Institute School of Public Health, The George Washington University
77. Meredith Minkler, DrPH, Professor Emerita of Health and Social Behavior, UC Berkeley School of Public Health
78. Anne K. Monroe, MD, MSPH, Associate Professor, Department of Epidemiology, Milken Institute School of Public Health, The George Washington University
79. Rachel Morello-Frosch, PhD, MPH, Professor, Environmental Health Sciences, Professor, Community Health Sciences, Department of Environmental Science, Policy and Management, UC Berkeley School of Public Health
80. MaryBeth Musumeci, JD, Associate Teaching Professor, Milken Institute School of Public Health, The George Washington University
81. Jonathan Oberlander, PhD, Professor, Department of Social Medicine, Professor, Department of Health Policy & Management, University of North Carolina at Chapel Hill

82. A. David Paltiel, PhD, Professor of Health Policy and Management, Yale School of Public Health
83. Wendy E. Parmet, JD, Matthews University Distinguished Professor of Law, Professor of Public, Policy and Urban Affairs, Northeastern University
84. Krista M. Perreira, PhD, Department of Social Medicine, UNC School of Medicine
85. Mark A. Peterson, PhD, Professor of Public Policy, Political Science, Health Policy and Management, and Law, Department of Public Policy, UCLA Meyer and Renee Luskin School of Public Affairs
86. Patricia Pittman, PhD, Professor of Health Policy and Management, Director of Health Workforce Research Center, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
87. Marsha Regenstein, PhD, Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
88. Dorit R. Reiss, PhD, LLB, Professor of Law, James Edgar Hervey Chair in Litigation, UC Law San Francisco

89. Richard Riegelman, MD, MPH, PhD, Professor of Epidemiology and Founding Dean, Milken Institute School of Public Health, The George Washington University
90. Barbara K. Rimer, DrPH, MPH, Alumni Distinguished Professor, Dean Emerita, UNC Gillings School of Global Public Health
91. Theresa Rohr-Kirchgraber, MD, MACP, FAMWA, Professor of Clinical Medicine, Augusta University/University of Georgia Medical Partnership
92. Sara Rosenbaum, JD, Professor Emerita, Health Law and Policy, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
93. Ani B. Satz, JD, PhD, Professor of Law and Public Health, Director, Project on Health Law, Policy and Ethics, Affiliated Professor of Business, Senior Faculty Fellow, Center for Ethics, Faculty Fellow, Emory Global Health Initiative, Emory University
94. Nadia N. Sawicki, JD, M. Bioethics, Georgia Reithal Professor of Law, Beazley Co-Chair in Health Law, Loyola University Chicago School of Law
95. Magda Schaler-Haynes, JD, MPH, Professor, Department of Health Policy and Management, Department of Population and Family Health,

Columbia University Mailman School of Public Health

96. Cason Schmit, JD, Assistant Professor, Director, Program in Health Law and Policy, Texas A&M University School of Public Health
97. Andy Schneider, JD, Research Professor of the Practice, McCourt School of Public Policy, Georgetown University
98. Jason L. Schwartz, PhD, Associate Professor of Public Health (Health Policy), Department of Health Policy and Management, Yale School of Public Health
99. Naomi Seiler, JD, Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
100. Stephen M. Shortell, PhD, MBA, MPH, Distinguished Professor of Health Policy and Management Emeritus and Dean Emeritus, School of Public Health, University of California Berkeley
101. Pam Silberman, JD, DrPH, Professor Emerita, Director, Executive Doctoral Program in Health Leadership, Department of Health Policy and Management, UNC Gillings School of Global Public Health
102. Laura A. Siminoff, PhD, Laura H. Carnell Professor of Public Health, Department of Social and Behavioral Sciences, Temple University

103. Michael S. Sinha, MD, JD, MPH, FCLM, Assistant Professor of Law, Center for Health Law Studies, Saint Louis University School of Law
104. Daniel Skinner, PhD, Professor of Health Policy, Ohio University
105. Becky Slifkin, PhD, Professor Emerita, Department of Health Policy and Management, UNC Gillings School of Global Health
106. Julia Strasser, DrPH, MPH, Director, Jacobs Institute of Women's Health, Assistant Research Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
107. John Swartzberg, MD, FACP, Clinical Professor Emeritus, Professor, Emeriti Academy, School of Public Health, Division of Infectious Diseases and Vaccinology, Chair, Editorial Board, UC Berkeley Wellness Letter, University of California
108. James M. Tielsch, PhD, Professor and Chair, Department of Global Health, Milken Institute School of Public Health, The George Washington University
109. Michael R. Ulrich, JD, MPH, Associate Professor of Health Law, Ethics, & Human Rights, Boston University School of Public Health, Boston University School of Law

110. Anushree Vichare, PhD, MBBS, MPH, Assistant Professor, Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University
111. Amita N. Vyas, PhD, MHS, Professor, Director, Maternal & Child Health Program, Department of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University
112. Jan Warren-Findlow, PhD, Professor and Chair, Department of Public Health Sciences, University of North Carolina Charlotte
113. Alan G. Wasserman, MD, MACP, Eugene Meyer Emeritus Professor of Medicine, Department of Medicine, The George Washington School of Medicine and Health Sciences
114. Richard M. Weinmeyer, JD, PhD, MPhil, MA, Assistant Professor of Law, Loyola University Chicago School of Law
115. Timothy M. Westmoreland, JD, Professor from Practice, Emeritus, Georgetown University School of Law